NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando Florida. Andrew M Evens, DO, MSc, Associate Professor of Medicine, Feinberg School of Medicine of Northwestern University and Director, Translational Therapeutics Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, presented the abstract (# 2840) titled “the Novel Organic Arsenical, Darinaparsin (ZIO-101), Induces Apoptosis through AKT and MEK/ERK Pathways in Hodgkin’s Lymphoma and T-Cell Lymphoma Cell Lines.”
